Dopavision

Dopavision is a digital therapeutics company based in Berlin, focused on innovative eye care solutions, particularly for myopia (nearsightedness) in children and adolescents. The company combines expertise in biopharmaceuticals, neurosciences, and ophthalmology to create accessible healthcare products designed for everyday use. Their flagship product, MyopiaX®, is a patented digital therapy that employs selective ocular light stimulation to non-invasively activate pathways that regulate eye growth. This child-friendly therapy integrates engaging games and educational content on standard consumer devices, making it easy for children to use with minimal parental supervision. Dopavision has conducted a clinical trial to evaluate the safety and efficacy of MyopiaX®, marking a significant step toward providing a non-invasive alternative for managing myopia progression. Dopavision's team consists of experts from various fields, including neuroscience and healthcare, with connections to prestigious institutions like the Max Planck Institute. Their mission is to address unmet needs in eye care through scientifically grounded, innovative solutions.

• Employees 12
• Founded 2017
• Annual Revenue $2000000
• Total Funding $17086956